Here are the 10-K annual reports from Moderna, Inc. (MRNA) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow MRNA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MRNA filings page.
Moderna reports on its mRNA-focused business, highlighting three commercial vaccines—Spikevax and mNEXSPIKE for COVID-19 and mRESVIA for RSV—and 2025 revenue of $1.9 billion, largely from COVID vaccines. The company emphasizes a broad pipeline across infectious disease, oncology and rare diseases, including 35 therapeutic and vaccine programs, six in late-stage development.
Key programs include the flu vaccine mRNA-1010 and flu+COVID combo mRNA-1083 under regulatory review, a norovirus candidate mRNA-1403 in a large Phase 3 trial, and rare disease therapies for propionic acidemia and methylmalonic acidemia in registrational paths. In oncology, individualized therapy intismeran autogene (mRNA-4157), partnered with Merck, has shown sustained recurrence-free survival benefit in high-risk melanoma and expanded into multiple Phase 2 and 3 trials.
Moderna details a global manufacturing network in the U.S., UK, Canada and Australia, purpose-built facilities for personalized cancer vaccines, and heavy investment in platform, AI and digital tools to speed design, development and production. The filing also outlines extensive business risks, including regulatory uncertainty, competition, manufacturing complexity, cybersecurity and continued net losses in 2024 and 2025.